
## The PK-Eye<sup>™</sup> for intraocular drug development



#### The PK-Eye<sup>™</sup> can be used to:

- Identify the best formulation technology
- Determine PK parameters (t<sub>max</sub>, C<sub>max</sub>, t<sub>1/2</sub>)
- · Determine impact of physiological variables (age)
- Assess stability and functional maintenance of activity
- Optimize the selection of dose and dose frequency
- · Generate unique data to support additional patent coverage
- · Compare activity and duration to known products
- Speed development of biosimilar/biobetter products
- Reduce program risk BEFORE moving into costly animal and human studies

## What is the PK-Eye™?

The PK-Eye<sup>™</sup> is a 2-compartment, aqueous outflow model scaled to the 2 interior compartments of the human eye.

Human clearance times for biologics can be accurately determined in real time.

Implants of retinal permeable drugs can be accurately estimated by IVIVCs.

Stability studies for extended release candidates during optimisation are much more easily conducted than in animals.

PK-Eye<sup>™</sup> (Ver 2) has been developed.

SAHAR AWWAD, 1.2 ALASTAIR LOCKWOOD, 1.2 STEVE BROCCHIP	NI, <sup>1,2</sup> PENG T. KHAW <sup>1</sup>
<sup>1</sup> National Institute for Health Research (NIHR) Biomedical Research Institute of Ophthalmology, London ECTV 9EL, United Kingdom <sup>2</sup> UCL School of Pharmacy, London WCTN 1AX, United Kingdom	Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL
Received 13 February 2015; revised 8 April 2015; accepted 8 Apr	il 2015
Published online 24 June 2015 in Wiley Online Library (wileyon	linelibrary.com). DOI 10.1002/jps.24480
MRTIFECT. A comparison of which we have been as the second weak of the	right acting ophthalms: the thingparties. Use studies show approach the from the model. The clearance times of proteins can be entimate exocutarities using phosphate-buffered same in the whomes cavity. I ophysed a cleanance time of all 1.3.1.3 shows which is comparison one implant or the dissolution of supervisions as a first spin in the vectors. I click and the studies of a candidate budges from in the vectors, click and addee on develop large large phosphate (large show the manuroution) Sciences published by Wiley Veroldcask, Jac. and the 5 Wile. In whom models phomesolitetics, proteins protein solution
INTRODUCTION Prolonging theoremic level of a drug within the vibrees to treat binding densess is used of the most important gashs in the second second second second second second second second second second second second second second second second second second seco	logge of the anticolor mechanism involved in binning could densem" will contain the first the log patient and have a regular based modificant, which fixed is to patient and have a regular densemble of the second densemble of the logge second densemble densemble of the second densemble of the logge second densemble densemble of the densemble of the logge second densemble of the regular have provided in the densemble of the dense of the second densemble of the densemble of the dense of the second densemble of the densemble of the densemble of the dense of the second dense of the densemble of the densemble of the dense of the second dense of the densemble of the densemble of the dense of the second dense of the densemble of the densemble of the dense of the second dense densemble of the densemble of the dense of the second dense densemble of the densemble of the dense of the second dense densemble of the densemble of the densemble of the second dense densemble of the densemble of the densemble of the densemble of the densemble of the densemble of the densemble of the densemble of the densemble of the densemble of the densemble of the densemble of the densemble of the densemble of the densemble of the densemble of the densemble of the densemble of
Comparison to Page T. Rave (Tableson + 44 201 400 4007; Pan + 444 97 406 4067; Ann + 41 201 753 4054; Baner (Tableson Honding) (Tableson + 44 201 753 500; Pan + 44 207 753 5042; Baner (Tableson + 201 400) Annual (Physican + 201 and (Tableson + 201 400)) (Annual + 201 400) Annual (Physican + 201 400) (Annual + 201 400) (Annual + 201 400) Annual (Physican + 201 400) (Annual + 201 400) (Annual + 201 400) Annual (Annual + 201 400) (Annual + 201 400) (Annual + 201 400) (Annual + 201 400) (Annual + 201 400) (Annual + 201 400) (Annual + 201 400) (Annual + 201 400) (Annual + 201 400) (Annual + 201 400) (Annual + 201 400) (Annual + 201 400) (Annual + 201 400) (Annual + 201 400) (Annual + 201 400) (Annual + 201 400) (Annual + 201 400) (Annual + 201 400)	proteins, $^{30,03,70}$ (2) the surface area of the retina is large con- pared to the anxiety hybrid membrane, and (3) permulal molecules can char via neveral routes through the RCS (e.g. gassive diffusion, active transport, biolong to melanic, loss conjustival hymphatics and epischeral voice, and metabolisme). The RCS presenting of the transport, the RCS (e.g. the RCS) experimenting <sup>20</sup> is it shough that the physicoleum ical properties of a drug can often be used to predict RC permutality, <sup>20</sup> and <sup>20</sup> it should be the start of the RCS (e.g. the start of the RCS) presenting the start of the start of the start of the start ical properties of a drug can often be used to predict RC permutality, <sup>20</sup> it is drug can often be used to predict RC



### The PK-Eye<sup>™</sup> enables:

- Accelerated formulation and late preclinical dose escalation studies that are not feasible using *in vivo* models to be conducted.
- High throughput formulation development and stability analysis of intraocular drug candidates at all stages of preclinical development.
- Identifies only the best candidates for radio-labelling studies and detailed *in vivo* and stability studies.
- Real time, 24/7 monitoring of the outflow of candidate drug formulations at controlled temperature.

# **OPTCEUTICS**